Tribute Pharmaceuticals Canada Inc (TBUFF) 0.9300 $TBUFF
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
PR Newswire - Fri Feb 05, 12:18PM CST
Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-
TRX.VN: 1.250 (-0.070), ARZ.TO: 6.69 (+0.07), POZN: 5.94 (-0.43)
Tribute Announces Results of Shareholder Vote
Marketwired - Mon Feb 01, 10:05AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement (the "Arrangement" with, among others, Aralez Pharmaceuticals Inc. ("Aralez" (see press release dated December 7, 2015), which forms part of the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN).
TRX.VN: 1.250 (-0.070), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction
Marketwire Canada - Thu Jan 21, 6:30AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that Tribute shareholders vote FOR the special resolution (the "Arrangement Resolution" to approve the previously announced transaction (the "Transaction" with Pozen Inc. ("Pozen" and combination under Aralez Pharmaceuticals Inc. ("Parent", to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, Toronto, Ontario.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote
Marketwired - Mon Jan 11, 8:43AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that the Management Information Circular dated January 5, 2016 (the "Circular" and accompanying materials for Tribute's special meeting to be held on February 1, 2016 (the "Meeting" relating to the previously announced proposed transaction (the "Transaction" with POZEN Inc. ("POZEN" and combination under Aralez Pharmaceuticals Inc. ("Parent", have been mailed to Tribute shareholders ("Tribute Shareholders". These materials are available online at Tribute's website at www.tributepharma.com or on SEDAR at www.sedar.com and on the United States Securities and Exchange Commission (the "SEC" website at www.sec.gov.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in Migraine Treatment
Marketwire Canada - Mon Jan 04, 6:30AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company", a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,632,375, entitled "Diclofenac Formulations and Method of Use." This patent, which was developed by APR Applied Pharma Research s.a. ("APR", a private, international corporation headquartered in Switzerland and focused on the development and commercialization of innovative healthcare products, is licensed exclusively to Tribute in Canada through a sub-license agreement with Depomed, Inc. ("Depomed". Depomed has the exclusive North American rights to Cambia(R) licensed with APR. The issuance of the new patent will expand Tribute's intellectual property protection for Cambia(R), currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age.
TRX.VN: 1.250 (-0.070)
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
Marketwired - Tue Dec 29, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Schedules Special Shareholder Meeting for February 1, 2016
Marketwired - Mon Dec 28, 8:28AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction
GlobeNewswire - Mon Dec 28, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announced that it has called a special meeting of its shareholders (the "Special Meeting" to approve a reorganization of its share capital pursuant to a statutory plan of arrangement (the "Share Reorganization". As discussed below, if approved, the Share Reorganization is expected to permit QLT to distribute common shares of Aralez Pharmaceuticals Inc. ("Aralez" to QLT shareholders in a tax efficient manner. It is anticipated that the Special Meeting will be held on February 11, 2016, in Vancouver, Canada.
QLTI: 1.41 (-0.03), TRX.VN: 1.250 (-0.070), QLT.TO: 1.82 (-0.02), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez Pharmaceuticals, a Canadian Domiciled Entity
GlobeNewswire - Mon Dec 07, 3:54PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announced today that it has agreed to revised terms regarding its previously announced agreement to provide equity financing in the amount of US$45 million in connection with the pending merger transaction between POZEN Inc. (Nasdaq
OZN) ("POZEN" and Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute". The revised terms were agreed to in connection with changes to the merger transaction announced earlier today by POZEN and Tribute.
QLTI: 1.41 (-0.03), TRX.VN: 1.250 (-0.070), QLT.TO: 1.82 (-0.02), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals
Marketwired - Mon Dec 07, 3:30PM CST
POZEN Inc. ("POZEN" (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute" (TSX VENTURE: TRX)(OTCQX: TBUFF) today confirmed their merger plans and announced that they have entered into an amended agreement and plan of merger, which among other things, moves the domicile for their proposed parent company, Aralez Pharmaceuticals Inc. ("Aralez", from Ireland to Canada. This alternative transaction structure, the parties believe, is in the best interest of their respective securityholders. The companies previously announced in June 2015 that POZEN would acquire Tribute and the combined company would be renamed Aralez Pharmaceuticals. With planned business operations in Ireland, Canada and the United States, the Canadian domicile offers a substantially similar corporate and tax structure to the previous Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute is incorporated and from where it has always operated.
TRX.VN: 1.250 (-0.070), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
POZEN and Tribute Provide Update on Pending Combination Transactions
Marketwired - Mon Nov 23, 8:02AM CST
POZEN Inc. ("POZEN" (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute" (TSX VENTURE: TRX) (OTCQX: TBUFF) today provided an update on their pending combination transactions. The companies have reviewed the recent guidance from the U.S. Treasury's Notice 2015-79 issued on November 19, 2015 and its potential impact on the proposed transaction. POZEN and Tribute remain committed to combining their respective businesses and are considering a Canadian domicile for Aralez Pharmaceuticals ("Aralez", the new parent entity for the combined companies. With the planned business operations in Ireland, Canada and the United States, the Canadian domicile offers substantially similar financial, tax and competitive advantages to an Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute was incorporated and from where it has always operated. The parties further believe that a Canadian domicile will be in compliance with the new Treasury Department Guidance and are working diligently and expeditiously on an alternative transaction structure that would be in the best interest of their respective securityholders, and the parties are further considering the Treasury Department Guidance as they continue to arrive at this alternative transaction structure.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Announces Third Quarter 2015 Results
Marketwired - Mon Nov 09, 4:01PM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a diversified healthcare company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the third quarter ended September 30, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars.
TRX.VN: 1.250 (-0.070)
POZEN and Tribute Announce Effectiveness of Registration Statement on Form S-4
BusinessWire - Fri Nov 06, 11:45AM CST
--Tribute Schedules Shareholder Meeting for December 9, 2015
TRX.VN: 1.250 (-0.070), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
PR Newswire - Fri Feb 05, 12:18PM CST
Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-
TRX.VN: 1.250 (-0.070), ARZ.TO: 6.69 (+0.07), POZN: 5.94 (-0.43)
Tribute Announces Results of Shareholder Vote
Marketwired - Mon Feb 01, 10:05AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement (the "Arrangement" with, among others, Aralez Pharmaceuticals Inc. ("Aralez" (see press release dated December 7, 2015), which forms part of the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN). TRX.VN: 1.250 (-0.070), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction
Marketwire Canada - Thu Jan 21, 6:30AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that Tribute shareholders vote FOR the special resolution (the "Arrangement Resolution" to approve the previously announced transaction (the "Transaction" with Pozen Inc. ("Pozen" and combination under Aralez Pharmaceuticals Inc. ("Parent", to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, Toronto, Ontario. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote
Marketwired - Mon Jan 11, 8:43AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that the Management Information Circular dated January 5, 2016 (the "Circular" and accompanying materials for Tribute's special meeting to be held on February 1, 2016 (the "Meeting" relating to the previously announced proposed transaction (the "Transaction" with POZEN Inc. ("POZEN" and combination under Aralez Pharmaceuticals Inc. ("Parent", have been mailed to Tribute shareholders ("Tribute Shareholders". These materials are available online at Tribute's website at www.tributepharma.com or on SEDAR at www.sedar.com and on the United States Securities and Exchange Commission (the "SEC" website at www.sec.gov. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in Migraine Treatment
Marketwire Canada - Mon Jan 04, 6:30AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"
, a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,632,375, entitled "Diclofenac Formulations and Method of Use." This patent, which was developed by APR Applied Pharma Research s.a. ("APR", a private, international corporation headquartered in Switzerland and focused on the development and commercialization of innovative healthcare products, is licensed exclusively to Tribute in Canada through a sub-license agreement with Depomed, Inc. ("Depomed". Depomed has the exclusive North American rights to Cambia(R) licensed with APR. The issuance of the new patent will expand Tribute's intellectual property protection for Cambia(R), currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age. TRX.VN: 1.250 (-0.070)
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
Marketwired - Tue Dec 29, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Schedules Special Shareholder Meeting for February 1, 2016
Marketwired - Mon Dec 28, 8:28AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction
GlobeNewswire - Mon Dec 28, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
today announced that it has called a special meeting of its shareholders (the "Special Meeting" to approve a reorganization of its share capital pursuant to a statutory plan of arrangement (the "Share Reorganization". As discussed below, if approved, the Share Reorganization is expected to permit QLT to distribute common shares of Aralez Pharmaceuticals Inc. ("Aralez" to QLT shareholders in a tax efficient manner. It is anticipated that the Special Meeting will be held on February 11, 2016, in Vancouver, Canada. QLTI: 1.41 (-0.03), TRX.VN: 1.250 (-0.070), QLT.TO: 1.82 (-0.02), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez Pharmaceuticals, a Canadian Domiciled Entity
GlobeNewswire - Mon Dec 07, 3:54PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
announced today that it has agreed to revised terms regarding its previously announced agreement to provide equity financing in the amount of US$45 million in connection with the pending merger transaction between POZEN Inc. (NasdaqOZN) ("POZEN" and Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute". The revised terms were agreed to in connection with changes to the merger transaction announced earlier today by POZEN and Tribute. QLTI: 1.41 (-0.03), TRX.VN: 1.250 (-0.070), QLT.TO: 1.82 (-0.02), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals
Marketwired - Mon Dec 07, 3:30PM CST
POZEN Inc. ("POZEN"
(NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute" (TSX VENTURE: TRX)(OTCQX: TBUFF) today confirmed their merger plans and announced that they have entered into an amended agreement and plan of merger, which among other things, moves the domicile for their proposed parent company, Aralez Pharmaceuticals Inc. ("Aralez", from Ireland to Canada. This alternative transaction structure, the parties believe, is in the best interest of their respective securityholders. The companies previously announced in June 2015 that POZEN would acquire Tribute and the combined company would be renamed Aralez Pharmaceuticals. With planned business operations in Ireland, Canada and the United States, the Canadian domicile offers a substantially similar corporate and tax structure to the previous Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute is incorporated and from where it has always operated. TRX.VN: 1.250 (-0.070), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
POZEN and Tribute Provide Update on Pending Combination Transactions
Marketwired - Mon Nov 23, 8:02AM CST
POZEN Inc. ("POZEN"
(NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute" (TSX VENTURE: TRX) (OTCQX: TBUFF) today provided an update on their pending combination transactions. The companies have reviewed the recent guidance from the U.S. Treasury's Notice 2015-79 issued on November 19, 2015 and its potential impact on the proposed transaction. POZEN and Tribute remain committed to combining their respective businesses and are considering a Canadian domicile for Aralez Pharmaceuticals ("Aralez", the new parent entity for the combined companies. With the planned business operations in Ireland, Canada and the United States, the Canadian domicile offers substantially similar financial, tax and competitive advantages to an Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute was incorporated and from where it has always operated. The parties further believe that a Canadian domicile will be in compliance with the new Treasury Department Guidance and are working diligently and expeditiously on an alternative transaction structure that would be in the best interest of their respective securityholders, and the parties are further considering the Treasury Department Guidance as they continue to arrive at this alternative transaction structure. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Announces Third Quarter 2015 Results
Marketwired - Mon Nov 09, 4:01PM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a diversified healthcare company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the third quarter ended September 30, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. TRX.VN: 1.250 (-0.070)
POZEN and Tribute Announce Effectiveness of Registration Statement on Form S-4
BusinessWire - Fri Nov 06, 11:45AM CST
--Tribute Schedules Shareholder Meeting for December 9, 2015
TRX.VN: 1.250 (-0.070), ARLZ: 5.21 (+0.01), POZN: 5.94 (-0.43)
